This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by MARX, S. J. Articles by BRANDI, M.-L. Search for Related Content PubMed PubMed Citation Articles by MARX, S. J. Articles by BRANDI, M.-L.

Mitogenic Activity on Parathyroid Cells in Plasma From Members of a Large Kindred With Multiple Endocrine Neoplasia Type 1

Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (S.J.M., K. G.D.A., M.-L.B.) Bethesda, Maryland 20892
The Belvedere Medical Center (J.G.) Carlisle, Pennsylvania 17013

Address all correspondence and requests for reprints to: Dr. Stephen Marx, Building 10, Room 9C-101, National Institutes of Health, Bethesda, Maryland 20892.

We tested plasma from 83 members of a large kindred with familial multiple endocrine neoplasia type 1 (FMENl) for mitogenic activity on cultured bovine parathyroid cells. We evaluated the age dependency of parathyroid mitogenic activity (PMA) in plasma from affected and unaffected members of the kindred, and we analyzed the relation of plasma PMA to indices of activity of parathyroid, pancreatic islet, and anterior pituitary tissue. Plasma PMA was higher in members expressing the FMENl gene than in their unaffected first, second, third, or fourth degree relatives (P < 0.05), and 10 of 20 members expressing the FMENl gene had plasma PMA above the 95% limit of the control range. Plasma PMA was not dependent on sex or age; the lack of age dependency and the high values in FMENl gene carriers suggested that plasma PMA is elevated in some FMENl gene carriers very early in life. Plasma PMA in known gene carriers varied significantly with one index of parathyroid function [plasma PMA was 2.5 times higher in the group with than in the group without prior parathyroidectomy (P < 0.005), an indicator of more severe prior parathyroid disease] and correlated positively, although not significantly so, with indices of pancreatic islet function (serum gastrin by RIA) and anterior pituitary function (serum PRL by RIA). In summary, (1) plasma PMA levels are high in many known carriers of the FMENl gene, (2) the high plasma PMA levels in FMENl may precede overt endocrine hyperfunction; and (3) high plasma PMA levels vary with one index of parathyroid function, but do not correlate with indices of pancreatic islet or anterior pituitary function in members expressing the FMENl gene. The high plasma PMA levels in FMENl may be the direct cause of hyperfunction of the parathyroids, but the relation of high plasma PMA to hyperfunction of the pancreatic islets and anterior pituitary is uncertain.

Received December 17, 1987.

This article has been cited by other articles:

				L. A. Lambert, S. E. Shapiro, J. E. Lee, N. D. Perrier, M. Truong, M. J. Wallace, A. O. Hoff, R. F. Gagel, and D. B. Evans Surgical Treatment of Hyperparathyroidism in Patients With Multiple Endocrine Neoplasia Type 1 Arch Surg, April 1, 2005; 140(4): 374 - 382. [Abstract] [Full Text] [PDF]